Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Matinas Biopharma Hl (MTNB)

Matinas Biopharma Hl (MTNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,391
  • Shares Outstanding, K 6,406
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,250 K
  • EBIT $ -9 M
  • EBITDA $ -8 M
  • 60-Month Beta 1.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.62
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.44
  • Most Recent Earnings $-0.40 on 11/10/25
  • Next Earnings Date 04/21/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7000 +20.21%
on 11/26/25
1.3300 -36.73%
on 11/10/25
-0.4385 (-34.26%)
since 11/07/25
3-Month
0.7000 +20.21%
on 11/26/25
2.1400 -60.68%
on 09/22/25
-0.7985 (-48.69%)
since 09/09/25
52-Week
0.4748 +77.23%
on 04/08/25
3.0900 -72.77%
on 08/15/25
+0.2309 (+37.82%)
since 12/09/24

Most Recent Stories

More News
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

GRCE : 3.47 (+3.58%)
ONVO : 2.04 (+1.49%)
MTNB : 0.8415 (-5.93%)
Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

MTNB : 0.8415 (-5.93%)
Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair

MTNB : 0.8415 (-5.93%)
Matinas BioPharma Receives NYSE Noncompliance Notice

MTNB : 0.8415 (-5.93%)
Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

MTNB : 0.8415 (-5.93%)
Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

75% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data in Late Q3/Early Q4 2022 FDA Provides Flexibility...

MTNB : 0.8415 (-5.93%)
Matinas BioPharma to Participate in the BTIG Biotechnology Conference

BEDMINSTER, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving...

MTNB : 0.8415 (-5.93%)
Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on August 11, 2022

BEDMINSTER, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical...

MTNB : 0.8415 (-5.93%)
Matinas BioPharma Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for MAT2203 for the Treatment of Cryptococcosis

BEDMINSTER, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving...

MTNB : 0.8415 (-5.93%)
Matinas BioPharma to Present at the LD Micro Invitational XII Conference

BEDMINSTER, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving...

MTNB : 0.8415 (-5.93%)

Business Summary

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines,...

See More

Key Turning Points

3rd Resistance Point 1.1727
2nd Resistance Point 1.0738
1st Resistance Point 0.9577
Last Price 0.8415
1st Support Level 0.7427
2nd Support Level 0.6438
3rd Support Level 0.5277

See More

52-Week High 3.0900
Fibonacci 61.8% 2.0910
Fibonacci 50% 1.7824
Fibonacci 38.2% 1.4738
Last Price 0.8415
52-Week Low 0.4748

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar